HelixTalk

Connect With COP

This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics. We're hoping that our real-life clinical pearls and discussions will help you stay up-to-date and improve your pharmacy knowledge.

How Do I Listen?

HelixTalk is available via , by , subscribing to our mailing list, or by listening to any episode in your browser (below).

Subscribe to Our Mailing List

Sean P. Kane, PharmD, BCPS and Khyati S. Patel, PharmD, BCACP sit at a table with a laptop, engaged in a discussion about their podcast HelixTalk.

HelixTalk Episodes

HelixTalk #191 - The Ultimate Guide to ARBs: An In-depth Drug Class Review

Date posted: June 23, 2025, 6:00 am

In this episode, we review the pharmacology, indications, adverse effects, monitoring, and unique drug characteristics of angiotensin receptor blockers (ARBs). 


HelixTalk #190 - Can’t Stop, Won’t Drop … The BP That Just Won’t Quit: Diagnosis and Treatment of Resistant Hypertension

Date posted: May 29, 2025, 2:10 pm

In this episode, we discuss the diagnosis and treatment of resistant hypertension, including a newer endothelin receptor antagonist (ERA) called aprocitentan (Tryvio®).


HelixTalk #189 - Mice, Macrophages, and Metabolism: Browning Keeps Obesity at Bay

Date posted: April 7, 2025, 8:35 am

In this episode, we discuss the very early stages of drug targets and drug development with Dr. Mohd Shahid, PhD. Dr. Shahid’s research involves the IER3 gene, which is an important modulator of the body’s inflammatory response via its action in major immune cells, including macrophages and T-cells, and plays a role in metabolic disorders such as obesity, diabetes, and atherosclerosis, revealing a previously unknown function of this protein.


HelixTalk #188 - The Clot Thickens: Key Updates from the 2025 Acute Coronary Syndromes Guidelines

Date posted: March 14, 2025, 1:41 pm

In this episode, we review the new 2025 ACC/AHA Acute Coronary Syndrome (ACS) guidelines, with a particular focus on guideline recommendations for analgesics, P2Y12 inhibitors, parenteral anticoagulation, and lipid management.